Duchenne muscular dystrophy: Quality of life among 95 patients evaluated using the life satisfaction index for adolescents;Distrofia muscular de Duchenne: Avaliação da qualidade de vida em 95 pacientes através do Life Satisfaction Index for Adolescents

Arquivos de Neuro-Psiquiatria

Volumn 69, Issue 1, 2011, Pages 19-22

  Simon, Valdecir A ^a   Dutra Resende, Maria Bernardete ^a   Simon, Margarete A V P ^b   Zanoteli, Edmar ^a,c   Reed, Umbertina Conti ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b University Sao Judas Tadeu   (Brazil)

^c AACD   (Brazil)

Author keywords

Duchenne muscular dystrophy; Life Satisfaction Index for Adolescents; Quality of life; Questionnaire; Steroid therapy

Indexed keywords

DEFLAZACORT; PREDNISOLONE;

ADOLESCENT; ARTICLE; CHILD; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; EVALUATION; HUMAN; LIFE SATISFACTION INDEX FOR ADOLESCENTS; MAJOR CLINICAL STUDY; RATING SCALE; STEROID THERAPY;

EID: 79952340717     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2011000100005     Document Type: Article

References (29)

1. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988;53:219-228.
2. Hoffman EP, Monaco AP, Feener CC, Kunkel LM. Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 1987; 238:347-350.
3. Hernández LBL, Cárdenas NAV, Padrón EL. Distrofia muscular de Duchenne: actualidad y perspectivas de tratamiento. Rev Neurol 2009;49:363-369.
4. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
5. Caromano FA. Características do portador de distrofia muscular de Duchenne: revisão. Arq Cienc Saude Unipar 1999;3:211-218.
6. Scott OM, Goddard C, Dubowitz V. Quantification of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 1982;5:291-301.
7. Steffensen BF, Lyager S, Werge B, et al. Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy:a longitudinal study. Dev Med Child Neurol 2002;44:623-632.
8. Santos NM, Rezende MM, Terni A, et al. Perfil clínico e funcional dos pacientes com distrofia muscular de Duchenne assistidos na Associação Brasileira de Distrofia Muscular (ABDIM). Rev Neurocienc 2006;14:15-22.
9. Carvalho CRF. Caracterização da evolução respiratória em distrofia muscular de Duchenne: implicações da força muscular respiratória máxima. Tese, Livre-docência. São Paulo: Faculdade de Medicina, Universidade de São Paulo, 2004.
10. Hartel JV, Granchelli JA, Hudecki MS, et al. Impact of prednisone on TGF - beta 1 and collagen in diaphragm muscle from mdx mice. Muscle Nerve 2001;24:428-432.
11. Parreira SL, Resende MB, Della Corte Peduto M, et al. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arq Neuropsiquiatr 2007;65:245-250.
12. Daftary SA, Crisanti M, Kalra M, et al. Strength in patients with Duchenne muscular dystrophy effect of long-term steroids on cough efficiency and respiratory muscle. Pediatrics 2007;119:320-324.
13. Pradhan S, Ghosh D, Srivastava NK, et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 2006;253:1309-1316.
14. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
15. Houde S, Filiatrault M, Fournier A. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200-206.
16. Toussaint M, Chatwin M, Soudon P. Mechanical ventilation in Duchenne patients with chronic respiratory insufficiency: clinical implications of 20 years published experience. Chron Respir Dis 2007;4:167-177.
17. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008: CD003725.
18. Bombardier C, Tugwell P. Methodologic considerations in functional assessment. J Rheumatol 1987;14 (Suppl 15):S6-S12.
19. Bowling A. Measuring disease. A review of disease-specific quality of life measurement scales. Edition 2. Philadelphia: Open University Press, 2001.
20. Teixeira-Salmela LF, Magalhães LC, Souza AC. Adaptação do perfil de saúde de Nottingham: um instrumento simples de avaliação da qualidade de vida. Cad Saúde Pública 2004;20:905-914.
21. Reid D, Renwick RM. Preliminary validation of a new instrument to measure life satisfation in adolescentes with neuromuscular disorders. Int J Rehabil Res 1994;17:184-188.
22. Rosner B. Fundamentals of Biostatistics. Ed 4. New York: Duxbury Press, 1994.
23. Gonçalves M, Dylewski V, Xavier e Chaves AC, et al. Qualidade de Vida: análise comparativa entre crianças com distrofia muscular de Duchenne e seus cuidadores. Rev Neurociênc 2008;16:275-279.
24. Assumpção JR, Kuczynski E, Sprovieri MH, Aranha E. Escala de Avaliação de Qualidade de Vida (AUQEI) - Autoquestionnaire Qualité de Vie Enfant Imagé. Arq Neuropsiquiatr 2000;58:119-127.
25. Melo L-AE, Moreno-Valdes MT. Evaluation of the quality of life of children with Duchenne's progressive muscular dystrophy. Rev Neurol 2007;45:81-87.
26. Ruta D, Garratt A, Abdalla M, Buckingham K, Russell I. The SF 36 health survey questionnaire. A valid measure of health status. BMJ 1993;307:448-449.
27. Ciconelli RM. Tradução para o português e validação do questionário genérico de avaliação de qualidade de vida do Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Tese de Doutorado. São Paulo: Escola Paulista de Medicina - UNIFESP, 1997.
28. Kohler M, Clarenbach CF, Bahler C, et al. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2009;80:320-325.
29. Bray P, Bundy AC, Ryan MM, North KN, Everett AJ. Health-related Quality of Life in boys with Duchenne muscular dystrophy: agreement between parents and their sons. J Child Neurol 2010 Mar 24. [Epub ahead of print]